Achiko
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tessinerplatz 7, Zürich, Zurich, 8002, S...Phone Number
+41 442666767Website
www.achiko.comRevenue
<$5 MillionStock Symbol
ACHIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Achiko
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and its sister digital mobile health technology division, Teman Sehat. The Company has created a unique healthtech capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management of Covid-19. AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesized and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialization rights. Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul, and Singapore.Explore more
Achiko Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Achiko your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Achiko had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Achiko has new funding data
Product Launch: Get notified when Achiko launches new products
Achiko, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Achiko
Check out if Achiko is spiking on competitors!
Earning: See what the market has to say on Achiko recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Achiko has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Achiko as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Achiko is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Achiko is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Achiko.
Achiko financials insights
Gather financial insights about Achiko, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$5.3M
2022
Debt
$12.7M
Debt
$1.3M
Achiko Tech Stack
A closer look at the technologies used by Achiko
Most Recent Scoops
Funding
Funding
Funding
Left Company
Executive Move
Achiko News & Media
Achiko AG Issues a Convocation Notice to its Shareholders for its Annual General Meeting on December 20, 2022
ZURICH, Switzerland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) has issued a convocation notice to its shareholders for the Company's Annual General Meeting taking place at 10:00 a.m. CET on December 20, 2022, in the offices of the Notary public Notariat Riesbach-Zurich, Kreuzstrasse 42, 8008 Zurich Zurich.Achiko AG Announces Corporate Update Webcast
Commercial Delivery of its Saliva-Based Covid-19 Test AptameX™ Has Commenced Commercial Delivery of its Saliva-Based Covid-19 Test AptameX™ Has CommencedAchiko AG Commences Commercial Deliveries in Indonesia
Commencing Commercial Deliveries of its Generation 2 of AptameX™ Covid-19 Tests Kits with Nahdlatul Ulama (DKI) in Jakarta, Indonesia Commencing Commercial Deliveries of its Generation 2 of AptameX™ Covid-19 Tests Kits with Nahdlatul Ulama (DKI) in Jakarta, IndonesiaAchiko AG Production and Company Update
ZURICH, Switzerland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX™ Covid-19 test kit. Generation 1 was successfully calibrated and delivered near perfect results earlier this year. Generation 2 is optimized
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Achiko
Sign Up For FreeTo access detailed company insights
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and its sister digital mobile health technology division, Teman Sehat. The Company has created a unique healthtech capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management... Read More
